Related Experiment Video
Updated: Jun 9, 2026
08:17
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
Published on: June 7, 2015
Stereotactic radiosurgery for lung tumors.
1Department of Cardiothoracic Surgery, Stanford University Medical Center, Stanford, California, USA. riwhyte@stanford.edu
Seminars in Thoracic and Cardiovascular Surgery
|September 4, 2010
Summary
Stereotactic radiosurgery (SRS) is an emerging lung cancer treatment for early-stage tumors. This review covers SRS history, efficacy, toxicity, and its comparison to surgery for lung cancer.
Area of Science:
- Oncology
- Radiation Oncology
- Thoracic Surgery
Background:
- Lung cancer is a leading cause of cancer mortality.
- Surgery is the standard for early-stage lung cancer.
- Stereotactic radiosurgery (SRS) is an evolving alternative therapy.
Purpose of the Study:
- To review the history of SRS for lung tumors.
- To summarize efficacy and toxicity data for SRS.
- To discuss controversies surrounding SRS in lung cancer treatment.
Main Methods:
- Literature review of SRS in lung cancer.
- Analysis of current efficacy and toxicity data.
- Discussion of ongoing clinical trials and controversies.
Main Results:
- SRS has transitioned from a niche treatment to a viable option for early-stage lung cancer.
- An international trial is comparing SRS to lobectomy in healthy patients.
- Data on SRS efficacy and toxicity are accumulating.
Conclusions:
- SRS is increasingly recognized as a significant treatment modality for early-stage lung cancer.
- Further research and comparative trials are essential.
- SRS offers a valuable alternative for patients unsuitable for surgery.
